Introduction
Protein kinases play important roles in the intracellular signaling pathways that regulate cell functions such as proliferation, differentiation, and survival.I nc ancer cells, expression of mutated protein kinase genes can cause over-activation of these intracellular signaling pathways, resultingi np romotion of malignant transformation. Therefore, drugs that inhibitthe activity of protein kinasesa re an important meanso ft reating cancers.
Kinase inhibitors are categorized as typeI inhibitors, which bind to the ATPb inding site of the target kinase;t ype II inhibitors, which bind to the ATPb inding site andt oaneighboring region;a nd type III inhibitors, which bind to an allosteric site. [1] Type Ii nhibitors generally have low selectivity,b ecause the amino acid sequence and structure of the ATPb inding pocket of kinases have high similarities. In addition to these three types,k inasei nhibitors are further classified into subdivisions with more specific criteria. [2] Gefitinib (trade name:I ressa) is at ype Ik inase inhibitor used for the treatment of advanced non-small-cell lung cancer that is positive for amutation in the epidermal growth factor receptor (EGFR) gene. [3, 4] The structure of gefitinib has a4 -anilinoquinazoline skeleton ( Figure 1 ). Although gefitinibi sc urrently in clinicalu se, seriousa dverse drug reactions such as interstitial lung diseasea nd respiratory dysfunction have been reported, [5] suggesting that gefitinib has unidentified off-target inhibitory effects.
Gefitinib is the molecular target drug for advanced non-smallcell lung cancer.T he primary target of gefitinibi st he positive mutationofepidermal growth factor receptor,but it also inhibits cyclin G-associated kinase (GAK).T or eveal the molecular bases of GAK and gefitinib binding, structurea nalyses were conducted and determined two forms of the gefitinib-bound nanobody·GAK kinase domain complex structures. The first form, GAK_1, haso ne gefitiniba tt he ATPb inding pocket, whereas the second form, GAK_2, binds one each in the ATP bindings ite and an ovel binding site adjacent to the activation segment C-terminal helix, au nique elemento ft he Numb-associated kinase family.I nt he novel binding site, gefitinibbinds in the hydrophobic groovea round the activations egment, disrupting the conserved hydrogen bonds for the catalytic activity.T hese structures suggest possibilities for the development of selective GAK inhibitors for viral infections, such as the hepatitis Cvirus. In addition to inhibiting signaling through EGFR( IC 50 = 14 nm), [6] Brehmer et al. have reported that gefitinib also inhibits cyclin G-associatedk inase (GAK) and receptor-interacting serine/threonine protein kinase 2( RICK;a lso known as RIPK2, RIP2, and CARDIAK) (IC 50 = 90 and 49 nm,r espectively), as determined by using ap roteomics approach. [6] GAK regulates clathrin-mediated membrane trafficking, [7] transcriptional coactivation, [8] andm itotic chromosomec ongression, [9] and is also essential forc ell growth. [10, 11] Knockout mice expressing the kinase-dead form of GAK develop respiratory dysfunction and die immediately after birth, suggestingt hat GAK inhibition is one of the underlying causes of the seriousa dverse drug reactions associated with gefitinib treatment. [12] GAK also phosphorylates the m subunit of adaptor protein 2, which induces rearrangement of its structure;t his inhibits adaptor proteinmediated trafficking in the endocytic pathway, [13] which is associated with hepatitis Cv irus entry into host cells and increased risk of developing Parkinson'sd isease. Therefore, GAK is ap otential therapeutic target fort he treatment of hepatitis Ca nd Parkinson'sd isease. [13] Investigations of the structural detailso f GAK inhibition will contribute not only to understanding the adversed rug reactions, but also to developing selective inhibitors for several severe diseases, such as Parkinson'sd isease.
GAK is composed of four domains:akinase domain in the N-terminus, aP TEN-like domain, ac lathrin-binding domain, and aJdomain at the C-terminus.T he kinase domain belongs to the Numb-associated kinase (NAK) family that includes MPSK1 (myristoylateda nd palmitoylated serine/threonine kinase 1), AAK1 (adaptor-associated kinase1), and BMP2 (bone morphogeneticp rotein 2)-inducible kinase, [14] the structures of which have all been solved. [15, 16] The active structures of these kinases all have al arge a-helix, including an activation segment C-terminal helix (ASCH)a tt he Cl obe, which allowsf or continuousk inase activity withoutt he need for phosphorylation of the activation loop.
Here, we report the crystal structureso ft wo GAK kinase domain·gefitinib·Nanobody (Nb) complexes.T he two structures differ in the number of gefitinibb inding sites:b oth structures possessacommon ATPb inding site;h owever,o ne also possesses as econdary binding site in as egment that is important for the catalytic activity of GAK, suggesting that gefitinib strongly inhibits GAK. The binding mode of gefitinibi nt he commonA TP binding site is similari nG AK and EGFR. To gether, these crystal structures provide important informationt hat will be useful for the structure-based design of drugs with greater selectivity for EGFR and GAK.
Results and Discussion

Structure of GAK Kinase Domain
Initially,w ea ttempted to determine the structure of the GAK kinase domain·gefitinib complex;h owever,t he crystal diffracted at al ow resolution (ca. 3.5 )a nd we were unablet od etermine the gefitinib electron density in the structure. Recently, high-resolution crystal structures of the active and inactive forms of GAK kinase domain in complex with Nbs were reported (Protein Data Bank [PDB] ID:4 C57 [2.55 ]a nd 4C59 [2.8 ] , respectively). [15] Therefore, in the present study,w eu sed ac ellfree synthesis system [17] to synthesize two Nbs and we were able to co-crystallize GAK kinase domain·gefitinib·Nb complexes. Consequently,t wo crystal forms (GAK_1 and GAK_2), which contain the 4C57 type Nb, wereo btaineda nd solved by using am olecular replacement methodw ith the first Nb (PDB ID:4 C57) as the search model;these structures wererefined to resolutions of 2.80 and 2.50 ,r espectively (see Table S1 and Figure2). Thus, using Nbs was effective for determiningt he structure of the GAK kinase domain·gefitinib complex.
The two GAK kinase domain structures both have ag eneral bilobal structure,c omprising al arger Clobe and as maller Figure 2 . Ribbondiagrams of the overall structures of the GAK kinase domain·gefitinib·nanobody complexes (GAK_1, green;GAK_2, cyan). Gefitinibm olecules are shownasp urple stick models.ASCH, activationsegment C-terminal helix. Nlobe ( Figure 2 ). Although the complexes crystallized with different crystal packing that included one or two complex molecules in the asymmetric unit, the root mean squared eviation (rmsd) value for the common Ca atoms of the GAK kinase domain in both crystal structures was 0.6 .Acomparison of GAK_1 and the previously reportedG AK kinase domain in complex with aN b( PDB ID:4 C57) [15] providedaC a rmsd of 0.9 ,indicating that the structures were almost identical.
GAK_1 and GAK_2a dopt an activec onformation, [2] featuring the DFG-ina nd aC-in configuration, which possesses as alt bridge between Lys69 at ac onserved active site in b3a nd Glu85 in aC, and an ordered activated segment including ASCH. ASCH is stabilized by hydrogen bondsf ormed between the conserved amino acids of the catalytic loop and the activation segment (Mg 2 + -binding loop, activation loop, P + 1l oop, and APE loop). The main difference between the two GAK structuresi st hat they differ in the number of gefitinib molecules that are bound:G AK_1i ncludes one gefitinib molecule bound to the ATPb inding site of the GAK kinase domain, whereas GAK_2 includes two gefitinib molecules-oneb ound to the ATPb inding site and one bound to ab inding site located in the Clobe.
Gefitinib Binding Affinity for the GAK Kinase Domain
In this study,w ec onducted as urface plasmon resonance (SPR) analysist od etermine the dissociation constant (K D )o fg efitinib for the GAK kinase domain. By adopting a1 :1 binding model of the steady-state affinity analysis, its K D was estimated as 15.4 nm,w hich is close to the previously reportedv alue. [18] Considering the existence of the second binding site in the GAK_2 structure, the SPR data were furthera nalyzed by the kinetic heterogenous ligand model.T he analysisi mplied the presenceo ft wo binding sites with high and low affinities: K D1 = 1.62 nm and K D2 = 285 nm.T hese affinities may correspond to the two binding sites in the GAK_2 crystal structure.
Both gefitinibb indings in GAK_2 occuri np ockets, and not at the crystal packing interface. Thus, the two crystal forms suggest that conformational variations appear in the different crystals. The GAK activation formi ss tabilized by Nb, which is located approximately 34 apart from ASCH. There is no intermolecular interaction around ASCH. Molecular contacts, such crystal packing, in the other part might influence the ligand affinities at the binding sites through the stability of the activated form. These interaction circumstances may underlie the different binding stoichiometries (1:1 and 1:2) in the different crystal forms (GAK_1 and GAK_2).
Gefitinib Binding to the ATPB inding Site
The electron densities of gefitinib in the ATPb inding pocket of GAK_1 and GAK_2w ere clearlyo bserved (Figure 3a,b) . In both structures, the anilinoquinazoline ring of gefitinibi sl ocated toward the ATPb inding pocket. The chloro group of the aniline ring of gefitinib is oriented to the Nlobe. The nitrogen atom of the quinazoline ring formsahydrogen bond with the backbonea mide group of Cys126. The binding of gefitinib with GAK_2 is stabilized by ah ydrogen bond network formed amongG lu85, Thr123, Phe192,C ys190, and three water molecules. The gefitinib molecule also contacts Leu46, Val54, and Ala67 in the roof of the pocket;G lu124 and Leu125 in the hinge region;a nd Lys127,G ly128, Gln129,a nd Leu180 in the floor of the cleft. The interaction mannersa re summarized in Figure S1 aa nd S1 b. The anilinoquinazoline ring of gefitinib bound to GAK_1a nd GAK_2 superimposes well. Ap ropylmorpholinog roup was added to improvet he pharmacokinetic properties of the inhibitor (Figure 1) . [19] In GAK_1 andG AK_2, the propylmorpholino group differently extends toward solvent region,and there is no specific interaction with GAK.
BindingMode of Gefitinib to GAK or EGFR
Six structures of the gefitinib·EGFR complex (PDB:4 WKQ,4 I22, 3UG2, 2ITO, 2ITY,a nd 2ITZ;t wo with wild-type and four with mutant EGFR) have been reported.
[20] EGFR(L858R) and EGFR(G719S) are gefitinib sensitive, whereas the other structures, which have asecond mutated T790M,are gefitinib resistant. In the gefitinib·EGFR complex, the aniline ring of gefitinib extends into the hydrophobic pocket of the ATPb inding cleft, and the nitrogen atom in the quinazoline ring of gefitinib forms only as ingle hydrogen bond witht he backbone amide of Met793 in the hinge region of EGFR. [20a] The propylmorpholino group is oriented differently in the gefitinib·EGFR complex as well as the gefitinib·GAK complex. To examine the causes of the serious adverse drug reactions associated with gefitiniba dministration, the amino acid sequence, overall structure, and binding mode with gefitinib of EGFR(L858R) and GAK_1w ere compared. EGFR(L858R), and GAK_1h as as equence identity of 13.5 %a nd as tructural similarity with an rmsd of 3.36 over 210 common Ca atoms and 0.72 for the common main chain atoms composing the ATPb inding site. Superimposing the two structures (Figure 3c )r evealed that the location of the anilinoquinazoline ring andi ts hydrogen bond with Cys129 in the GAK kinase domain [corresponding to Met793 in EGFR(L858R)] are conserved.T he gefitinibb inding pocket regioni sa lso similar.H owever,i nE GFR(L858R), ar igid amino acid, Pro794, in the hinge regiona ppears to provide ac haracteristic structural environment.
Second Gefitinib BindingSite in the GAK Kinase Domain
An ovel second gefitinibb inding site was observedi nt he activation segmento fG AK_2 (Figure 4a ). Crystals tructures with two binding sites have been reported for MPSK1 [16] and Casein kinase 1 g1( PDB ID:2 BUJ and 2CMW,r espectively). However, the second binding sites in the structures of these two kinases are at the surfaceo ft he Nlobe, which is different to the location of the second binding site in GAK_2. In GAK 2, the anilinoquinazoline ring is located parallel to ASCH, and the propylmorpholino group extends towardt he aCh elix. The anilinoquinazoline ring of gefitinib is surroundedb yahydrophobic environment formed by the side chains of His200, Val214, IIe218, Ser194, Asn221, and Thr222, and the main chain of Gly193. Ac ation-p interaction is formed between the guanidino group of Arg172a nd the quinazoline skeleton of gefitinib, and as tacking interaction is formed between the imidazole ring of His200 and the aniline ring. In addition, hydrogen bonds betweenA rg172 and Gln244, mediated by two water molecules, stabilize the bindingo ft he second gefitinib molecule to GAK_2. The interaction mannersare summarized in Figure S2 aa nd S2 b. Through the binding of the second gefitinib molecule, ASCH movest oward the solvent region by 3.5 compared with in GAK_1, which disrupts the hydrogen bonds between Asp173-Thr223 and Ser194-Asn221 (Figure 4b ). The former hydrogen bond corresponds with the substrate-induced hydrogen bond between Asp166 and Thr201i nc AMPdependentp rotein kinase. [21] Substitutiono fT hr201w ith an alanineresidue in cAMP-dependent protein kinase abolishes its enzyme activity. [21] The latter hydrogen bond stabilizes the active conformation by connecting the activation loop and ASCH. These hydrogen bonds are important to anchor the Cterminal region of the active loop and for the kinase activity. [22] Considering the role of theseh ydrogen bonds, the binding of gefitinib to the second binding site likely furtheri nhibits substrate binding activity.
Comparisono ft he SecondBinding Sites among NAK Family Kinases
The crystal structures of the NAK family kinasesh ave been determined [23] for MPSK1 (PDB:2 BUJ), AAK1 (4WSQ), and BMP2K (4W9X). [16] The superimposition of these kinases and GAK_1 produced rmsd values of 2.2 (GAK-MPSK1), 1.8 (GAK-AAK1), and 1.4 (GAK-BMP2K). These structurals imilarities can be correlatedw ith the sequence conservations:2 3.2 %( GAK-MPSK1), 37.0 %( GAK-AAK1), and 37.1 %( GAK-BMPK2).
Although ASCHi sauniquem otif for the NAK family kinases, the motif length and sequence vary among the kinases ( Figure 5 ). The second gefitinibb inding site is present in this region. Ac omparison among the NAKf amilyk inase structures suggested that hydrophobic contacts might be possible for each kinase, because hydrophobic interactions are achieved with aliphatic side chain moieties. The other interactions in GAK around the second binding site are 1) ac ation-p interaction formed between the guanidinog roup of Arg172a nd the quinazoline skeleton of gefitinib, 2) as tacking interaction formed between the imidazole ring of His200a nd the aniline ring, and 3) hydrogenb onds between Arg172 and Gln244, mediated by two water molecules (see above). Among these amino acids (Arg172, His200, and Gln244), Arg172i sc onserved in the NAK family kinases (Figure 5 ), whereas His200 and Gln244 are not conserved. Therefore, the stacking interaction and the water-mediated hydrogen bonds with gefitinibs eem GAK is reportedly involved in the hepatitis Cv irus life cycle, and thus an inhibitor of GAK can be considered as an anti-hepatitis Ca gent. [18] Selective inhibitors for the NAK family kinases to inhibitt he ATPb inding site have been explored. [23] Our results suggest that gefitinibb inding at the second site is as elective interaction for both GAK and gefitinib. The second bindingsite, as well as the ATPbinding site, may be apotential target site for GAK-selective inhibitor development.
Conclusions
Here, we solved the crystal structures of two GAK kinase domain·gefitinib·Nb complexes andd iscovered an ovel second gefitinibb inding site in GAK. The two crystal structures revealed that the kinase activity of GAK and EGFR are inhibited by gefitinib throught he same inhibitory mechanism.I na ddition, this is the first time as econd binding site nearA SCH has been reported, whichi su nique in the NAK family kinases. Detailed information on the structures of EGFR andG AK is important for the design of highly selective drugs targeting these proteins,a sd emonstrated by our discoveryt hat gefitinibb inding at both the first and second site causess trong inhibition. Although the binding of ligandsa ts econdary sites is yet to be reported for other NAK family kinases, the present results suggest that the second binding site may be al atent compoundbinding site in NAK family kinases.T he structurali nformation presented here will be useful to direct in silico screening for the development of novel drugs with greater selectivity for GAK.
Experimental Section
Cloning of GAK AD NA fragment containing the kinase domain (25-335) of the human GAK gene (OriGene Te chnologies, USA) was amplified by means of PCR and sub-cloned into the expression vector pCR2.1TOPO (Life Te chnologies, USA) with an N-terminal fusion consisting of an N-terminal "N11-tag" (MKDHLIHNHHKHEHAHAEH, affinityt ag for nickel resin) and aT EV protease cleavage site. Genes encoding the Nbs were converted from two amino acid sequences (PDB ID:4 C57 and 4C58) and synthesized by Eurofins Genomics (Japan), and the DNA fragments were amplified and subcloned in as imilar way to GAK.
Protein Expression and Purification
GAK and the two Nbs were synthesized by using ac ell-free protein synthesis system. [24] In the case of the Nbs, 400 mgmL À1 of Escherichia coli disulfide isomerase DsbC and oxidized glutathione (GSSG) (Nacalai Te sque, Japan) was added to the reaction solution to promote the formation of disulfide bonds and optimize the redox conditions. [25] The solutions were then applied to aH isTrap column (GE Healthcare, UK) pre-equilibrated with 20 mm Tris (pH 8.0), 1 m NaCl, 20 mm imidazole, and 10 %g lycerol. The samples were eluted with ab uffer containing 500 mm imidazole, and the N11-tag was cleaved with TEV protease at 4 8Co vernight in ab uffer containing 20 mm Tris (pH 8.0), 500 m NaCl, 20 mm imidazole, and 10 %g lycerol. Then, the solutions were applied to aH isTrap column, followed by the elution with ab uffer containing 500 mm imidazole, to remove the N11-tag. The flow-through fractions (GAK) and the eluted fractions (Nbs) were further purified by using an ion-exchange column (Resource Q; GE Healthcare, UK) and a size-exclusion chromatography column (Superdex75;G EH ealthcare, UK) in af inal buffer containing 20 mm Tris (pH 8.0), 300 mm NaCl, 2mm DTT,a nd 10 %g lycerol for GAK, and 50 mm Tris (pH 7.5) and 100 mm NaCl for the Nbs. Purified GAK and Nb were mixed in a1:2 molar ratio, and then the complexes were separated by using as ize-exclusion chromatography column with ab uffer containing 50 mm Tris-HCl (pH 7.5) and 100 mm NaCl. Samples were concentrated to af inal concentration of 10 mg mL À1 and stored at À80 8C.
Crystallization and Data Collection
The GAK kinase domain·Nb complexes were incubated with 0.5 mm gefitinib (purity > 99.9 %, HPLC;F unakoshi, Japan) and 1% DMSO. To obtain the GAK_1 crystal, GAK kinase domain·Nb complex was mixed in areservoir solution containing a0.17 m ammonium sulfate, 0.085 m sodium cacodylate trihydrate (pH 6.5), 25.5 % PEG8000, and 15 %g lycerol, and co-crystallized by using the sitting drop method at 20 8C. To obtain the GAK_2 crystal, the GAK kinase domain·Nb complex was mixed with ar eservoir solution containing a0 .2 m ammonium sulfate, 0.1 m sodium cacodylate trihydrate (pH 6.5), and 15 %P EG8000, and co-crystallized by using the hanging drop method at 20 8C. The deposited crystals were refined in the same conditions used for the seeding. Both crystals were flashfrozen in liquid nitrogen with 20 %g lycerol as the cryoprotectant.
Structure Determination and Refinement
The diffraction data for the GAK_1 and GAK_2 crystals were collected by using beamline BL32XU at SPring-8 (Hyogo, Japan) and processed by using the HKL2000, [26] XDS, [27] and CCP4 software suite. [28] Molecular replacement was performed with the Phaser program [29] by using the coordinates of Nb and the GAK kinase domain (PDB ID:4 C57) as the search models. The model was built with COOT, [30] and refinement was performed with PHENIX software. [31] The geometry restraints of gefitinib were generated with the eLBOW module of PHENIX. Ramachandran statistics were calculated with the MolProbity. [32] Structural models were drawn by using PyMOL software (the Pymol Molecular Graphics System, Version 1.8, Schrodinger,L LC). Structural comparisons were performed by using the Superpose program in the CCP4 suite.
Surface Plasmon Resonance
Experiments were conducted on aB IAcore TM T200 instrument (GE Healthcare Life Sciences). GAK was immobilized on aS ensor Chip CM5, using an Amine Coupling Kit (GE Healthcare Life Sciences). All data were collected in buffer containing 10 mm HEPES (pH 7.3), 150 mm NaCl, 1mm MgCl 2 ,a nd 0.005 %s urfactant P-20. Serial concentrations (0-50 mm)o fg efitinib were injected, and the responses were measured. The experiments were performed with five sample concentrations, in triplicate. Dissociation constants (K D )w ere computed by fitting to a1:1 interaction model in the steady-state affinity analysis and ah eterogeneous ligand model in the kinetic analysis, using the Biacore software, BIAevaluation (GE Healthcare Life Sciences). The stoichiometry was calculated based on the theoreti- 
Accession Codes
The coordinates and structure factors of the final models of the Nb·GAK kinase domain complexes were deposited in the PDB (PDB IDs:5 Y7Z and 5Y80).
